HC Wainwright Reaffirms “Buy” Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $37.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 130.01% from the stock’s previous close.

PHAR has been the subject of a number of other reports. Oppenheimer reiterated an “outperform” rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 13th. Zacks Research cut Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $39.00.

Pharming Group Stock Performance

Shares of NASDAQ:PHAR traded up $0.08 during midday trading on Tuesday, reaching $16.09. 11,271 shares of the company’s stock traded hands, compared to its average volume of 29,196. Pharming Group has a one year low of $7.50 and a one year high of $21.34. The company has a market cap of $1.13 billion, a price-to-earnings ratio of 1,608.40 and a beta of 0.04. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59. The stock has a 50 day moving average of $16.94 and a 200 day moving average of $16.13.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The company had revenue of $106.50 million for the quarter, compared to analysts’ expectations of $111.76 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. As a group, equities research analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group in the 2nd quarter worth about $32,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group during the 4th quarter worth $224,000. Millennium Management LLC acquired a new stake in shares of Pharming Group during the fourth quarter worth $360,000. Finally, NewEdge Advisors LLC increased its stake in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.